Viveve Medical, Inc.

Good afternoon and welcome to the Vaviv first quarter 2022 financial results and corporate update conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing star, then zero. Please also note this event is being recorded. And now I'll turn the call over to Jeannie Swindle, Vaviv's Senior Director of Corporate Communications.

Thank you, Operator, and welcome, everyone. Before we begin, we would like to remind you that this conference call may contain forward-looking statements regarding future events or the future financial performance of the company. Any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the corporation's cost, timing, progress, and results of its clinical trials, including the initiation, progress of, and results from our pursuit trial and whether the clinical trial will support the intended uses for treatment of stress urinary incontinence, or SUI, in the United States, fluctuation of global market economic conditions, impact of the novel coronavirus on clinical development, regulatory review and clearances, manufacturing system placements and utilization projections, expectations, plans, beliefs, and prospects. These statements are based on judgments and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are described more fully in the company's annual report on Form 10-K and other filings made with the SEC, which are also available on the company's website. Also, any forward-looking statements represent management's view only as of the date of this conference call and should not be relied upon as representing management's views as of any subsequent date. Speaking today will be Scott Durbin, the V's Chief Executive Officer, and Jim Robbins, Senior Vice President of Finance and Administration. I will now turn the call over to Jim.

Thank you, Jeannie. Good afternoon, everyone, and thank you for joining the call today. I will begin today's call with a brief review of our first quarter 2022 financial results. I will then turn the call over to Scott, who will provide a corporate update. Today, we reported total revenue for the first quarter of $1.6 million from the global placement of 11 systems and approximately 2,750 consumable treatment tips. As of the end of the first quarter 2022, the company had an installed base of 895 of these systems worldwide. First quarter, total operating expenses were $5.8 million, compared to $5.5 million for the same period last year. The increase is mainly a result of the company's efforts to advance our Stress Urinary Incontinence, or SUI, development program and support our currently underway pursuit clinical trial in the U.S., as well as engineering and development work related to our next-generation products and product line improvements. As of March 31, 2022, we reported cash and cash equivalents of $14 million. Thanks. I'll now turn the conference call over to Scott.